Lexeo Therapeutics, Inc.
LXEO
$7.50
-$0.18-2.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 6.62% | -14.27% | |||
| Gross Profit | -6.62% | 14.27% | |||
| SG&A Expenses | -62.72% | -4.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -29.46% | -9.22% | |||
| Operating Income | 29.46% | 9.22% | |||
| Income Before Tax | 22.30% | 20.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 22.30% | 20.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 22.30% | 20.07% | |||
| EBIT | 29.46% | 9.22% | |||
| EBITDA | 29.63% | 9.26% | |||
| EPS Basic | 44.48% | 39.25% | |||
| Normalized Basic EPS | 50.93% | 31.42% | |||
| EPS Diluted | 44.48% | 39.25% | |||
| Normalized Diluted EPS | 50.93% | 31.42% | |||
| Average Basic Shares Outstanding | 39.95% | 31.59% | |||
| Average Diluted Shares Outstanding | 39.95% | 31.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||